San Diego, CA, United States of America

Eoin C O'Leary


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2006-2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eoin C O'Leary: Innovator in Inflammatory Condition Treatments

Introduction

Eoin C O'Leary is a notable inventor based in San Diego, CA, who has made significant contributions to the field of medical treatments. With a focus on inflammatory conditions, his work has led to the development of innovative methods and compounds that have the potential to improve patient outcomes.

Latest Patents

Eoin C O'Leary holds two patents that highlight his expertise in treating inflammatory diseases. His latest patents include methods for treating inflammatory conditions or inhibiting JNK. This invention relates to administering an effective amount of a Pyrazoloanthrone Derivative to patients in need. Additionally, he has developed compounds that act as selective inhibitors of JNK, which are useful in treating a variety of conditions responsive to JNK inhibition. These compounds and their pharmaceutical compositions represent a significant advancement in therapeutic options for patients.

Career Highlights

Eoin C O'Leary is associated with Signal Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in his field. His work has not only contributed to the scientific community but has also paved the way for new treatment methodologies.

Collaborations

Eoin has collaborated with notable colleagues such as Brydon L Bennett and Shripad S Bhagwat, enhancing the research efforts at Signal Pharmaceuticals, Inc. Their combined expertise has fostered an environment of innovation and discovery.

Conclusion

Eoin C O'Leary's contributions to the treatment of inflammatory conditions through his patents and collaborations underscore his role as a leading inventor in the medical field. His work continues to inspire advancements in therapeutic solutions for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…